Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients.
Marta López-MaraverAna Serrano-CombarroBelén Atienza-MateoNatividad Del ValIvette Casafont-SoléRafael B Melero-GonzalezAlba Pérez-LinazaJerusalem Calvo GutiérrezNatalia Mena-VázquezNuria Vegas-RevengaLucía Domínguez-CasasJesús Loarce MartosCilia Amparo Peralta GinésCarolina Diez MorrondoLorena Pérez AlbaladejoRubén López SánchezMª Guadalupe Manzano CanabalAnahy Mª Brandy-GarcíaPatricia López ViejoGema BonillaOlga Maiz-AlonsoCarmen Carrasco-CuberoMarta Garijo BufortMireia MorenoAna Urruticoechea-AranaSergio Ordóñez-PalauCarmen González-MontagutEmilio Giner SerretJuan Ramón De Dios Jiménez De AberasturiFernando Lozano MorilloTomás Vázquez RodríguezPatricia E CarreiraJuan María Blanco MadrigalBelén Miguel IbáñezMarina Rodríguez LópezCarlos Fernández-DíazJavier LoriceraIván Ferraz-AmaroDiego Ferrer-PargadaSantos CastañedaRicardo Blanconull nullPublished in: Seminars in arthritis and rheumatism (2024)
In patients with RA-ILD, ABA seems to be equally effective regardless of the route of administration.
Keyphrases
- interstitial lung disease
- rheumatoid arthritis
- disease activity
- transcription factor
- quality improvement
- high dose
- study protocol
- ankylosing spondylitis
- clinical trial
- systemic sclerosis
- arabidopsis thaliana
- double blind
- cross sectional
- rheumatoid arthritis patients
- randomized controlled trial
- low dose
- systemic lupus erythematosus